EP1221961A4 - Induktion einer starken immunantwort gegen ein tumor-assoziiertes selbst-antigen - Google Patents

Induktion einer starken immunantwort gegen ein tumor-assoziiertes selbst-antigen

Info

Publication number
EP1221961A4
EP1221961A4 EP00970926A EP00970926A EP1221961A4 EP 1221961 A4 EP1221961 A4 EP 1221961A4 EP 00970926 A EP00970926 A EP 00970926A EP 00970926 A EP00970926 A EP 00970926A EP 1221961 A4 EP1221961 A4 EP 1221961A4
Authority
EP
European Patent Office
Prior art keywords
induction
self
immune response
associated antigen
tumor associated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00970926A
Other languages
English (en)
French (fr)
Other versions
EP1221961A1 (de
Inventor
Soldano Ferrone
Ashwani K Sood
Xin-Hui Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ROSWELL PARK MEMORIAL INSTITUTE
ROSWELL PARK MEMORIAL INST
Original Assignee
ROSWELL PARK MEMORIAL INSTITUTE
ROSWELL PARK MEMORIAL INST
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ROSWELL PARK MEMORIAL INSTITUTE, ROSWELL PARK MEMORIAL INST filed Critical ROSWELL PARK MEMORIAL INSTITUTE
Publication of EP1221961A1 publication Critical patent/EP1221961A1/de
Publication of EP1221961A4 publication Critical patent/EP1221961A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C07K16/4258—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
    • C07K16/4266—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig against anti-tumor receptor Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00119—Melanoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP00970926A 1999-10-13 2000-10-13 Induktion einer starken immunantwort gegen ein tumor-assoziiertes selbst-antigen Withdrawn EP1221961A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15915399P 1999-10-13 1999-10-13
US159153P 1999-10-13
PCT/US2000/028517 WO2001026672A1 (en) 1999-10-13 2000-10-13 Induction of a strong immune response to a self-tumor associated antigen

Publications (2)

Publication Number Publication Date
EP1221961A1 EP1221961A1 (de) 2002-07-17
EP1221961A4 true EP1221961A4 (de) 2004-03-31

Family

ID=22571310

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00970926A Withdrawn EP1221961A4 (de) 1999-10-13 2000-10-13 Induktion einer starken immunantwort gegen ein tumor-assoziiertes selbst-antigen

Country Status (5)

Country Link
EP (1) EP1221961A4 (de)
JP (1) JP2003514774A (de)
AU (1) AU8024100A (de)
CA (1) CA2385186A1 (de)
WO (1) WO2001026672A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE50111493D1 (de) * 2001-09-03 2007-01-04 Bio Life Science Forschungs & Entwicklungsgesellschaft Mbh Antigen-Mimotope und Vakzine gegen Krebserkrankungen
CN1902221A (zh) 2003-12-31 2007-01-24 先灵-普劳有限公司 基于中和表位的生长增强疫苗
AR051853A1 (es) 2004-12-30 2007-02-14 Schering Plough Ltd Vacuna para aumentar el crecimiento basada en epitopes neutralizantes
US8318162B2 (en) 2009-07-16 2012-11-27 Xoma Technology Ltd. Antibodies to high molecular weight melanoma associated antigen

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0759442A1 (de) * 1987-09-10 1997-02-26 Oncogen Limited Partnership Immuntherapie mit Antiidiotyp-Antikörpern
WO1997023237A1 (en) * 1995-12-22 1997-07-03 Immunomedics, Inc. Use of immunoconjugates to enhance the efficacy of multi-stage cascade boosting vaccines
US5780029A (en) * 1989-11-14 1998-07-14 New York Medical College Antidiotypic monoclonal antibodies for treatment of melanoma
WO2000038515A1 (en) * 1998-12-24 2000-07-06 New York Medical College Peptide mimics useful for treating disease

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0759442A1 (de) * 1987-09-10 1997-02-26 Oncogen Limited Partnership Immuntherapie mit Antiidiotyp-Antikörpern
US5780029A (en) * 1989-11-14 1998-07-14 New York Medical College Antidiotypic monoclonal antibodies for treatment of melanoma
WO1997023237A1 (en) * 1995-12-22 1997-07-03 Immunomedics, Inc. Use of immunoconjugates to enhance the efficacy of multi-stage cascade boosting vaccines
WO2000038515A1 (en) * 1998-12-24 2000-07-06 New York Medical College Peptide mimics useful for treating disease

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
DURRANT L G ET AL: "Development of second generation monoclonal antibodies recognising Lewis-y!b antigen by anti-idiotypic immunisation", HYBRIDOMA, vol. 12, no. 6, 1993, pages 647 - 660, XP008005496, ISSN: 0272-457X *
DYALL R ET AL: "HETEROCLITIC IMMUNIZATION INDUCES TUMOR IMMUNITY", JOURNAL OF EXPERIMENTAL MEDICINE, TOKYO, JP, vol. 188, no. 9, 2 November 1998 (1998-11-02), pages 1553 - 1561, XP002947142, ISSN: 0022-1007 *
FERRONE SOLDANO: "Active specific immunotherapy of human melanoma with mouse anti-idiotypic (anti-id) monoclonal antibodies (MAB)", MEDICAL INTELLIGENCE UNIT;IMMUNOTHERAPY OF MALIGNANT MELANOMA, 1996, Chapman and Hall, Inc., 29 West 35th Street, New York, New York, USA; Chapman and Hall Ltd., 2-6 Boundary Row, London SE1 8HN, England, pages 73 - 95, XP009024959, ISBN: 0-412-10491-1 *
PARKHURST M R ET AL: "Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues.", JOURNAL OF IMMUNOLOGY (BALTIMORE, MD.: 1950) UNITED STATES 15 SEP 1996, vol. 157, no. 6, 15 September 1996 (1996-09-15), pages 2539 - 2548, XP002096010, ISSN: 0022-1767 *
ROSENBERG S A ET AL: "Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma", NATURE MEDICINE, NATURE PUBLISHING, CO, US, vol. 4, no. 3, 1 March 1998 (1998-03-01), pages 321 - 327, XP002091661, ISSN: 1078-8956 *
See also references of WO0126672A1 *
WANG X ET AL: "IMMUNOTHERAPY OF MELANOMA: PEPTIDE MIMICS OF A HUMAN HIGH MOLECULARWEIGHT-MELANOMA ASSOCIATED ANTIGEN", MEDICINA, BUENOS AIRES, AR, vol. 60, no. SUPPL 2, August 2000 (2000-08-01), pages 48 - 50, XP001053496, ISSN: 0025-7680 *

Also Published As

Publication number Publication date
AU8024100A (en) 2001-04-23
WO2001026672A1 (en) 2001-04-19
JP2003514774A (ja) 2003-04-22
WO2001026672A9 (en) 2002-08-01
EP1221961A1 (de) 2002-07-17
CA2385186A1 (en) 2001-04-19

Similar Documents

Publication Publication Date Title
AU6449996A (en) Improved antibodies to Plasmodium falciparum
AU4835001A (en) Antibodies to human cd154
SI1163000T1 (sl) Vakcina proti antigenom iz bakterij
PL341160A1 (en) Novel superficial antigen
HUP9801242A3 (en) Hepatitis b vaccine
GB9930802D0 (en) Cyclone collector
GB9911569D0 (en) Antibodies
IL156276A0 (en) Induction of tolerance
IL121041A0 (en) Immunogenic compositions for induction of anti-tumor immunity
EP1022948A4 (de) Induktion von immunreaktionen auf von einem rekombinanten adeno-assoziierten virus exprimierte antigene
IL149458A0 (en) Induction of mucosal immunity by vaccination via the skin route
HUP0300354A3 (en) Hiv immune adjuvant therapy
AU8024100A (en) Induction of a strong immune response to a self-tumor associated antigen
AU2002249917A1 (en) Induction of immune responses to isoaspartyl-modified antigens
IL144130A0 (en) Modulation of immune response by ribavirin
AU7585998A (en) Controlling immune response to specific antigens
EP0686039A4 (de) Methode zur verstärkung der immunantwort auf orale vakzine
AU6604701A (en) Method to induce the TH1 immune response
AU7831898A (en) Induction of immune tolerance by immunotoxin
NO20021642L (no) Infraröd emitter med elektromagnetisk induksjon
IL142069A0 (en) Methods of downmodulating the immune response to therapeutic proteins
GB9915419D0 (en) Antigens
GB0014437D0 (en) Immune response stimulation
EP1244684A4 (de) I cryptosporidium/i sporozoit-antigene
AU2001266669A1 (en) Adjuvant preparation for the induction of specific immunity

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020422

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

A4 Supplementary search report drawn up and despatched

Effective date: 20040213

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61K 31/70 B

Ipc: 7A 61K 39/40 B

Ipc: 7A 61K 39/00 B

Ipc: 7C 07K 16/42 B

Ipc: 7A 61K 39/44 B

Ipc: 7A 01N 43/04 B

Ipc: 7A 61K 39/42 B

Ipc: 7A 61K 38/00 A

Ipc: 7A 61K 39/395 B

Ipc: 7C 07K 7/08 B

17Q First examination report despatched

Effective date: 20051019

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20080501